DGM
ELEV

Darwin Global Management’s Elevation Oncology ELEV Stock Holding History

Darwin Global Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,916,290
Closed -$4.81M – 8
2024
Q2 		$4.81M Sell
1,916,290
-416,638
-18% -$1.57M 0.56% 9
2024
Q1 		$12M Buy
+2,332,928
New +$7.56M 1.59% 10

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Darwin Global Management's ELEV Position: Q3 2024 in Review

Darwin Global Management sold out of Elevation Oncology (ELEV) in Q3 2024, closing a stake of 1,916,290 shares — an estimated $4.81M sold.

Darwin Global Management first reported a position in ELEV in Q1 2024 and held it in 2 quarters. The position peaked at $12M in Q1 2024. 68 funds tracked by Wall St. Rank hold ELEV as of Q3 2024.

  • Darwin Global Management reported no remaining Elevation Oncology position as of Q3 2024 after selling out during the quarter.
  • Darwin Global Management sold 1,916,290 Elevation Oncology shares in Q3 2024, an estimated $4.81M.
  • Darwin Global Management first reported a position in Elevation Oncology in Q1 2024 and held it in 2 quarters.
  • Darwin Global Management's Elevation Oncology position peaked at $12M in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2024.

Based on Darwin Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.